3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Myeloid, Acute
6
Hodgkin Disease
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Myelodysplastic Syndromes
5
Lymphoma, Non-Hodgkin
3
Burkitt Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myeloproliferative Disorders
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Hematologic Neoplasms
2
Solid Tumors
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Myelodysplastic-Myeloproliferative Diseases
1
Multi-centric Castleman's Disease
1
Malignant mesenchymal tumor
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lymphadenopathy
1
Interventions
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Filgrastim
×
30 days
×
Clear all
No trials found.